Association of body roundness index with cardiovascular disease and all‐cause mortality among Chinese adults

Diabetes Obesity and Metabolism, Journal Year: 2025, Volume and Issue: unknown

Published: Feb. 19, 2025

Abstract Aims To determine the impact of body roundness index (BRI) on 10‐year risk cardiovascular disease (CVD) and all‐cause mortality in Chinese adults. Materials Methods We utilized data from a nationwide prospective cohort 165 785 adults (aged ≥40 years, free CVD cancer at baseline), which was extracted China Cardiometabolic Disease Cancer Cohort (4C). Cox regression restricted cubic splines quantified BRI‐outcome associations identified optimal BRI cutoffs. Results During median follow‐up 10.1 we documented 10 538 events 8679 deaths. A monotonic increasing dose–response association observed between risk, while exhibited U‐shaped relationship ( p for non‐linear <0.001), with nadir 3.9. Gender differences indicated that increased associated higher men. As age increases, excess diminishes, significant harmful effect low individuals aged ≥75 years. Moreover, inclusion model significantly enhanced C‐statistic prediction by 0.00412 <0.001) 0.00045 = 0.0097). Conclusions Our findings indicate positive mortality. These underscore importance assessing mortality, particularly when considering different genders groups.

Language: Английский

---

Cardiometabolic Markers in Algerian Obese Subjects with and Without Type 2 Diabetes: Adipocytokine Imbalance as a Risk Factor

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(5), P. 1770 - 1770

Published: March 6, 2025

Background/Objectives: An increase in body fat is linked to abnormalities energy metabolism. We aimed at determining cardiometabolic risk Algerian participants with obesity alone and or without type 2 diabetes. The study measured the concentrations of circulating adipocytokines (leptin, adiponectin, resistin), tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6) identify examine how imbalances may affect parameters health. Methods: (n = 300) were recruited divided into three groups: control, obese, diabetics (with two sub-groups: obesity). Insulin resistance was evaluated using HOMA-IR, while ELISA used measure adipocytokines. Atherogenic index plasma (AIP), adiponectin-leptin ratio (ALR), visceral adiposity (VAI) also assessed. One-way ANOVA compare diabetes groups control one (p < 0.05). Logistic regression analysis conducted strengthen robustness statistical correlations. Results: Participants reduced (ALR) elevated levels resistin, TNF-α, IL-6 are found be higher cardiovascular diseases. imbalance adipocytokine caused by a decrease adiponectin concentrations, an pro-inflammatory that maintain exacerbate induces hyperinsulinemia, exposing individuals high Conclusions: Given ALR functional biomarker inflammation, insulin resistance, adipose tissue dysfunction, targeting could potentially therapeutic approach coping obesity-related risks. Mediterranean diet, weight loss, increased physical activity can key components promote healthy through ALR.

Language: Английский

---

Diagnosing Heart Failure with Preserved Ejection Fraction in Obese Patients

Journal of Clinical Medicine, Journal Year: 2025, Volume and Issue: 14(6), P. 1980 - 1980

Published: March 14, 2025

Obesity is a current pandemic that sets all affected individuals at risk of heart failure (HF), and the majority them will develop clinical syndrome HF with preserved ejection fraction (HFpEF). The diagnosis HFpEF challenging as it based on detection subtle functional structural remodeling leads to diastolic dysfunction increased left ventricular (LV) filling pressures raised natriuretic peptides (NPs). accurate even more in patients who are obese, since echocardiographic imaging quality may be suboptimal, parameters for evaluation cardiac structure indexed body surface area (BSA) thus underestimate severity remodeling, NPs obese have lower normal threshold. Moreover, prone atrial fibrillation (AF) pulmonary hypertension (PH), making strenuous. review aims offer insights different scenarios—patients scenarios—such sinus rhythm, fibrillation, case hypertension—by applying multimodality diagnostic algorithms.

Language: Английский

---

Treatment options for heart failure in individuals with overweight or obesity: a review

Future Cardiology, Journal Year: 2025, Volume and Issue: unknown, P. 1 - 15

Published: March 18, 2025

Obesity and heart failure are interlaced global epidemics, each contributing to significant morbidity mortality. is not only a risk-factor for failure, but also complicates its management, by distinctive pathophysiological mechanisms cumulative comorbidities, requiring tailored treatment plan. To present current options in individuals with overweight/obesity, emphasizing available pharmacological therapies, non-pharmacological strategies, the management of related comorbidities. We conducted comprehensive literature review regarding results treatments including cornerstone interventions as well emerging therapeutic options. Specific drug classes, angiotensin receptor-neprilysin inhibitors, mineralocorticoid receptor antagonists, sodium-glucose cotransporter-2 have demonstrated consistent efficacy irrespective body mass index, while diuretics remain key fluid management. Glucagon-like peptide-1 agonists shown promising improving relevant outcomes warrant further research. Non-pharmacological approaches, weight-loss strategies lifestyle modifications, improve symptoms, exercise tolerance quality life. Managing overweight/obesity requires multidisciplinary, individualized approach integrating Emerging therapies preventive arise address unique challenges this population provide improved outcomes.

Language: Английский

---

Suicide and Self-Harm Events With GLP-1 Receptor Agonists in Adults With Diabetes or Obesity

JAMA Psychiatry, Journal Year: 2025, Volume and Issue: unknown

Published: March 19, 2025

Importance Bariatric surgery, once the criterion standard in obesity treatment, has a small but concerning association with increased suicidality. Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), originally developed to treat diabetes, now provide substantial efficacy treatment of obesity. However, concerns risk suicidality these medicines have been raised. Objective To evaluate and self-harm randomized, placebo-controlled trials GLP-1 RAs adults diabetes or Data Sources MEDLINE, Embase, ClinicalTrials.gov, Cochrane databases were systematically searched from inception August 29, 2023. Study Selection Reports randomized clinical (RCTs) lasting 6 more months comparing placebo for published peer-reviewed journals identified. Two independent reviewers screened all search-identified studies inclusion. Records outcomes queried primary papers, ClinicalTrials.gov entries, corresponding authors. Extraction Synthesis researchers abstracted data assessed quality validity using PRISMA guidelines. pooled random-effects models. Main Outcomes Measures Pooled incidence completed attempted suicide, occurrences suicidal ideation, self-harm. Results A total 27 144 RCTs meeting inclusion criteria recorded suicide and/or self-harm-related events included 32 357 individuals receiving 046 treated placebo, over 74 740 68 095 person-years follow-up, respectively. Event was very low RA (0.044 per 100 person-years) (0.040 groups, no statistically significant difference (rate ratio [RR], 0.76; 95% CI, 0.48-1.21; P = .24). Subgroup analyses did not suggest differences based on status used. Five considered at bias due loss than 5% participants follow-up. Otherwise, found be heterogeneous nor high bias. Conclusions Relevance There is unlikely an increase suicide-related adverse among within context RCTs. While findings may further ease about effects, continued monitoring warranted identify particular patients who as extended use expands.

Language: Английский

---